Soluble TRAIL could enhance bone destruction acting on Rank-ligand in estrogen-independent human breast cancer cell line MDA-MB-231

Acta Histochemica

Volumn 112, Issue 2, 2010, Pages 189-192

  Nicolin, Vanessa ^a   Narducci, Paola ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Bone metastasis; Breast cancer; Osteoclastogenesis; Receptor activator factor kappa B ligand (RANKL); TNF related apoptosis inducing ligand (TRAIL)

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ARTICLE; AUTOCRINE EFFECT; BONE DESTRUCTION; BONE MATRIX; BREAST CANCER; CANCER CELL; CELL FUNCTION; CELL INTERACTION; CELL SECRETION; CONTROLLED STUDY; DISEASE COURSE; HOST CELL; HUMAN; HUMAN CELL; MICROENVIRONMENT; OSTEOLYSIS; PARACRINE SIGNALING; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RECEPTOR UPREGULATION;

BONE AND BONES; BREAST NEOPLASMS; CELL LINE, TUMOR; ESTROGENS; FEMALE; HUMANS; OSTEOLYSIS; OSTEOPROTEGERIN; PARACRINE COMMUNICATION; RANK LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND; UP-REGULATION;

EID: 75549086040     PISSN: 00651281     EISSN: 16180372     Source Type: Journal    
DOI: 10.1016/j.acthis.2008.09.011     Document Type: Article

References (12)

1. Bouralexis S., Clayer M., Atkins G.J., Labrinidis A., Hay S., Graves S., et al. Sensitivity of fresh isolates of soft tissue sarcoma, osteosarcoma and giant cell tumour cells to Apo2L/TRAIL and doxorubicin. Int J Oncol 2004, 24:1263-1270.
2. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
3. Cheng X., Kinosaki M., Takami M., Choi Y., Zhang H., Murali R. Disabling of receptor activator of nuclear factor-B (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo. J Biol Chem 2004, 279:8269-8277.
4. Colucci S., Brunetti G., Rizzi R., Zonno A., Mori G., Colaianni G., et al. T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. Blood 2004, 104:3722-3730.
5. Kitazawa S., Kitazawa R. RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol 2002, 198:228-236.
6. Kostenuik P.J., Singh G., Suyama K.L., Orr F.W. Stimulation of bone resorption results in a selective increase in the growth rate of spontaneously metastatic Walker 256 cancer cells in bone. Clin Exp Metastasis 1992, 10:411-418.
7. Lau Y.S., Danks L., Sun S.G., Fox S., Sabokbar A., Harris A., et al. RANKL-dependent and RANKL-independent mechanisms of macrophage-osteoclast differentiation in breast cancer. Breast Cancer Res Treat 2007, 105:7-16.
8. Miyashita T., Kawakami A., Nakashima T., Yamasaki S., Tamai M., Tanaka F., et al. Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells. Clin Exp Immunol 2004, 137:430-436.
9. Park H.R., Min S.K., Cho H.D., Kim D.H., Shin H.S., Park Y.E. Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis. J Korean Med Sci 2003, 18:541-546.
10. Sandra F., Hendarmin L., Nakamura S. Osteoprotegerin (OPG) binds with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): suppression of TRAIL-induced apoptosis in ameloblastomas. Oral Oncol 2006, 42:415-420.
11. Thomas R.J., Guise T.A., Yin J.J., Elliott J., Horwood N.J., Martin T.J., et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999, 140:4451-4458.
12. Vitovski S., Phillips J.S., Sayers J., Croucher P.I. Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J Biol Chem 2007, 282:31601-31609.